机构:[1]Hebei Med Univ, Hosp 4, Dept Nucl Med, Shijiazhuang, Peoples R China医技科室核医学科河北医科大学第四医院[2]Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Peoples R China[3]Baoding No 1 Cent Hosp, Dept Nucl Med, Baoding, Peoples R China[4]Hebei Gen Hosp, Dept Nucl Med, Shijiazhuang, Peoples R China
Objective: The aim of this study was to develop an F-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) radiomic model for predicting mediastinal lymph node metastasis (LNM) in presurgical patients with lung adenocarcinoma.Methods: The study enrolled 320 patients with lung adenocarcinoma (288 internal and 32 external cases) and extracted 190 radiomic features using the LIFEx package. Optimal radiomic features to build a radiomic model were selected using the least absolute shrinkage and selection operator algorithm. Logistic regression was used to build the clinical and complex (combined radiomic and clinical variables) models.Results: Ten radiomic features were selected. In the training group, the area under the receiver operating characteristic curve of the complex model was significantly higher than that of the radiomic and clinical models [0.924 (95% CI: 0.887-0.961) vs. 0.863 (95% CI: 0.814-0.912; p = 0.001) and 0.838 (95% CI: 0.783-0.894; p = 0.000), respectively]. The sensitivity, specificity, accuracy, and positive and negative predictive values of the radiomic model were 0.857, 0.790, 0.811, and 0.651 and 0.924, respectively, which were better than that of visual evaluation (0.539, 0.724, 0.667, and 0.472 and 0.775, respectively) and PET semiquantitative analyses (0.619, 0.732, 0.697, and 0.513 and 0.808, respectively).Conclusions: F-18-FDG PET/CT radiomics showed good predictive performance for LNM and improved the N-stage accuracy of lung adenocarcinoma.
基金:
Health
Commission Foundation of Hebei Province (No.20210720)
and the Hebei Medical Applicable Technology Tracking
Project (No.GL2011-52).
语种:
外文
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2025]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区肿瘤学4 区药学4 区核医学
最新[2025]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区肿瘤学4 区药学4 区核医学
JCR分区:
出版当年[2024]版:
无
最新[2023]版:
Q2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3MEDICINE, RESEARCH & EXPERIMENTALQ3ONCOLOGYQ3PHARMACOLOGY & PHARMACY
第一作者机构:[1]Hebei Med Univ, Hosp 4, Dept Nucl Med, Shijiazhuang, Peoples R China[2]Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Peoples R China
通讯作者:
通讯机构:[1]Hebei Med Univ, Hosp 4, Dept Nucl Med, Shijiazhuang, Peoples R China[2]Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Peoples R China[*1]Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University 12 Jiankang Road, Shijiazhuang 050011, China
推荐引用方式(GB/T 7714):
Dai Meng,Wang Na,Zhao Xinming,et al.Value of Presurgical F-18-FDG PET/CT Radiomics for Predicting Mediastinal Lymph Node Metastasis in Patients with Lung Adenocarcinoma[J].CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS.2024,39(8):600-610.doi:10.1089/cbr.2022.0038.
APA:
Dai, Meng,Wang, Na,Zhao, Xinming,Zhang, Jianyuan,Zhang, Zhaoqi...&Chen, Xiaolin.(2024).Value of Presurgical F-18-FDG PET/CT Radiomics for Predicting Mediastinal Lymph Node Metastasis in Patients with Lung Adenocarcinoma.CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,39,(8)
MLA:
Dai, Meng,et al."Value of Presurgical F-18-FDG PET/CT Radiomics for Predicting Mediastinal Lymph Node Metastasis in Patients with Lung Adenocarcinoma".CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 39..8(2024):600-610